UT-SAVIA-HEALTH
12.12.2022 13:53:42 CET | Business Wire | Press release
SaVia Health, a clinician-led healthcare SaaS company that creates and embeds patient care processes alongside electronic medical records (EMR), announced it raised an $8.5 million Seed round. The round was led by Intel Capital with participation from Kickstart, Peterson Ventures, Tom Burton, the founder of Health Catalyst, and Dr. Brent James, a professor at Stanford and renowned luminary in the healthcare quality improvement field.
SaVia Health was founded by a clinician, Dr. Will Caldwell, and a group of veteran healthcare software engineers led by David Edwards based in Salt Lake City, UT, seeking to provide clinicians with the ability to self-author clinical care pathways and provide clinical advice at the point of care.
“When I first saw clinicians using the SaVia tools, I knew the platform was something special. Never in my 21 years of clinical practice have I seen a piece of technology so fiercely embraced by clinicians,” said Dr. Will Caldwell, co-founder and CEO of SaVia Health. “Clinicians can finally design, implement, and modify care processes in a way that mirrors the rapidly evolving clinical landscape.”
“SaVia is a game changer when it comes to process redesign that enables deep operational and clinical improvement,” said Tom Burton, co-founder and Strategic Advisor of Health Catalyst. “With SaVia, dynamic workflow data capture changes can be made in minutes rather than weeks or months accelerating the speed of process improvement.”
Today, SaVia Health provides clinicians and administrators with a versatile software tool that transforms paper-based care processes into digital workflows, embedding them directly into the EMR. As a result, clinicians have real-time clinical advice at their fingertips. By standardizing care along best practice guidelines, mistakes are avoided and patients achieve better outcomes.
“Intermountain [Healthcare] caregivers have been using SaVia’s technology for years to provide the best possible care to our patients. SaVia’s tools enable front-line caregivers to consistently deliver best practices as part of their clinical workflows,” said Raj Srivastava, Senior Medical Executive Director at Intermountain Healthcare Delivery Institute. “We are thrilled to continue partnering with SaVia as an independent company to continue improving patient outcomes.”
“Patient care faces several challenges, including smoothly integrating the latest technology into existing processes,” said Nick Washburn, Senior Managing Director at Intel Capital. “SaVia is seamlessly changing the game for clinicians by translating data into guidance on what steps to take and when to best serve each patient.”
With this funding round, the company will further develop the self-authoring platform, expand its existing library of off-the-shelf applications, and focus on rapidly driving sales.
About SaVia Health
SaVia Health is a healthcare technology company based in Salt Lake City, UT that provides SaaS based process improvement software targeted at health systems, self-insured corporations, and large physician groups both in the United States and abroad. To learn more, visit saviahealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005152/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
